HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Biomodulatory metronomic therapy induces PET-negative remission in chemo- and brentuximab-refractory Hodgkin lymphoma.

AuthorsPeter Ugocsai, Daniel Wolff, Karin Menhart, Dirk Hellwig, Ernst Holler, Wolfgang Herr, Albrecht Reichle
JournalBritish journal of haematology (Br J Haematol) Vol. 172 Issue 2 Pg. 290-3 (Jan 2016) ISSN: 1365-2141 [Electronic] England
PMID25944562 (Publication Type: Case Reports, Letter)
Chemical References
  • Immunoconjugates
  • Immunologic Factors
  • Brentuximab Vedotin
Topics
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Brentuximab Vedotin
  • Drug Administration Schedule
  • Female
  • Hodgkin Disease (drug therapy)
  • Humans
  • Immunoconjugates (administration & dosage)
  • Immunologic Factors (administration & dosage)
  • Male
  • Positron-Emission Tomography
  • Remission Induction
  • Salvage Therapy (methods)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: